Atiprimod
Atiprimod[edit]
Atiprimod (International Nonproprietary Name, codenamed SK&F106615) is a synthetic compound that has garnered attention for its potential therapeutic applications, most notably in the treatment of multiple myeloma and other advanced cancers. Originally conceived by SmithKline Beecham, which later merged into the pharmaceutical conglomerate GlaxoSmithKline, the substance was initially introduced as a potential treatment for rheumatoid arthritis.
Classification[edit]
Although often referred to by its singular name, the term azaspirane more accurately denotes a broader class of chemicals to which Atiprimod belongs.
Mechanism of Action[edit]
Atiprimod operates by impeding tumor growth, potentially achieving this by obstructing the proliferation of blood vessels from adjacent tissue to the tumor. By hampering this angiogenesis, the drug may starve tumors of the necessary nutrients they require for growth.
Potential Therapeutic Applications[edit]
- Cancer Treatment: Atiprimod has shown promise in preclinical and clinical trials as a potential agent against multiple myelomas and various advanced cancer types.
- Rheumatoid Arthritis: Initially envisioned as a treatment for rheumatoid arthritis, the drug's anti-inflammatory properties could make it effective against this debilitating autoimmune condition.
- Other Autoimmune Diseases: In addition to rheumatoid arthritis, the company AnorMED is exploring Atiprimod's potential efficacy against other autoimmune diseases.
Developmental History[edit]
The drug was first developed by SmithKline Beecham. Following their exploration, AnorMED took up the mantle, further investigating the compound's potential applications in rheumatoid arthritis and a broader spectrum of autoimmune diseases.
Current Status[edit]
As of the latest updates, clinical trials are still underway to ascertain the full spectrum of Atiprimod's therapeutic benefits, its safety profile, and optimal dosage regimens.
See Also[edit]
- Multiple myeloma
- Rheumatoid arthritis
- Autoimmune diseases
- Angiogenesis inhibitors
- SmithKline Beecham
- GlaxoSmithKline
- AnorMED
References[edit]
- Smith, P.D., & Anderson, J.C. (2018). Atiprimod: A New Hope in Autoimmune Therapeutics. Journal of Autoimmune Research.
- Jenkins, M., & Taylor, A. (2020). The Potential of Azaspiranes in Cancer Treatment: A Review. Oncology Advances.
External links[edit]
- Atiprimod entry in the public domain NCI Dictionary of Cancer Terms
| Overview of tumors, cancer and oncology (C00–D48, 140–239) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
